Rixmin 400 Tablet, a prescription drug, is manufactured in various forms such as Tablet. Hepatic Encephalopathy are some of its major therapeutic uses. Other than this, Rixmin 400 Tablet has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Rixmin 400 Tablet. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. This information has been provided in detail in the dosage section.
The side effects typically associated with Rixmin 400 Tablet include Flatulence, Bloating or fullness, Constipation. While these are the most often observed Rixmin 400 Tablet side effects, there are can be others also. These have been listed below. Such side effects of Rixmin 400 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Rixmin 400 Tablet is Severe for pregnant women and Severe for women who are breastfeeding. Further, the section on Rixmin 400 Tablet related warnings talks about Rixmin 400 Tablet's effects on the liver, heart and kidney.
Other conditions have been mentioned below in the Rixmin 400 Tablet contraindications section.
Drug reaction of Rixmin 400 Tablet with other medicines has been reported. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Rixmin 400 Tablet is considered safe while driving, and is addictive.
Rixmin 400 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| 13 - 18 years (Adolescent) |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Rixmin 400 Tablet is used -
Moderate
Mild
Common
Is the use of Rixmin 400 Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Rixmin. If you are pregnant, do not take Rixmin without a doctor's advice.
Is the use of Rixmin 400 Tablet safe during breastfeeding?
Rixmin may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Rixmin 400 Tablet on the Kidneys?
Rixmin does not damage the kidneys.
What is the effect of Rixmin 400 Tablet on the Liver?
Rixmin may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Rixmin 400 Tablet on the Heart?
You can take Rixmin without any fear of damage to the heart.
Rixmin 400 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Rixmin 400 Tablet unless your doctor advises you to do so -
Is this Rixmin 400 Tablet habit forming or addictive?
No, you will not get addicted to Rixmin 400 Tablet.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking Rixmin 400 Tablet since it will not make you feel sleepy.
Is it safe?
Yes, but take Rixmin 400 Tablet only as per medical advice.
Is it able to treat mental disorders?
No, Rixmin 400 Tablet is not used to treat mental disorders.
Interaction between Food and Rixmin 400 Tablet
Taking Rixmin 400 Tablet with food is safe.
Interaction between Alcohol and Rixmin 400 Tablet
Due to lack of research, there is no information about the side effects of taking Rixmin 400 Tablet with alcohol.
Yes, Rixmin may cause orange urine because it is an analog of rifampicin. This side effect is reversible and unharmful in nature which goes away after discontinuation of this drug.
Rixmin works by inhibiting the bacterial protein synthesis which is essential for bacterial growth. The absence of these proteins results in stunned bacterial growth due to which bacteria is not able to survive. For hepatic encephalopathy Rixmin works by inhibiting the growth of enteric ammonia-producing bacteria which are present in our gut, this results in the indirect reduction of serum ammonia level. In irritable bowel syndrome with diarrhea, how Rixmin works are still unknown but it is presumed that it works by changing the bacterial flora in small intestine and reduction in gas.
Discontinuing Rixmin on your own can increase the chances of bacterial resistance and infection relapse. It is recommended that you always consult your doctor if you have decided to discontinue this medicine.
Rixmin is a brand name of rifaximin and it comes in the form of tablet and syrup. It is a prescription drug and a broad-spectrum antibiotic which is used in the prevention of travelers’ diarrhea (TD) caused by bacteria Escherichia coli and to reduce the risk of hepatic encephalopathy (a brain disorder that causes decline in functioning of the brain due to accumulation of ammonia in which results from the liver damage) along with lactulose. It is also used in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
No, Rixmin does not cause weight gain. It has not been reported by the patients who are taking this drug but Rixmin has been reported to cause weight loss in a few patients with travelers’ diarrhea. If you notice any unusual rapid weight changes after taking this drug then discuss with it your doctor and follow his/her instructions.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xifaxan® (rifaximin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 681-683
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1096-1097
